Skip to main content
Equibles
VRTX logo

VRTX · Vertex Pharmaceuticals Inc · Metrics

Track VRTX — free

Use VRTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$523.93 -11.24 (-2.10%) At close · Oct 23
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$132.80B
Shares
253.46M
Volume · Oct 23 833.46K Avg daily vol (3M) 1.18M

VRTX metrics

112 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$523.93
Market cap
$132.80B

Price action

20 metrics
Price change (1W)
+4.8%
Price change (30D)
-0.4%
Price change (3M)
+9.8%
Price change (6M)
+21.8%
Price change (YTD)
+15.6%
Price change (1Y)
+24.0%
Trailing year
Price change (5Y)
+185.5%
52-week high
$557.96
52-week low
$409.47
Change from 52-week high
-6.1%
Change from 52-week low
+28.0%
Annualized volatility
29.1%
Annualized volatility (3M)
27.7%
Beta
0.5
RSI (14D)
55.1
Price vs SMA 50
+0.2%
Price vs SMA 200
+9.8%
Avg volume (3M)
1.18M
Relative volume
0.7
Average dollar volume
$606.63M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
253.46M

Valuation

12 metrics
P / E (TTM)
30.5
Trailing earnings · reciprocal yield 3.3%
PEG ratio
3.8
EV / revenue
9.9×
reciprocal yield 10.1%
EV / EBITDA
25.0×
reciprocal yield 4.0%
EV / EBIT
26.2×
reciprocal yield 3.8%
P / sales
10.6×
reciprocal yield 9.5%
P / book
6.6
reciprocal yield 15.2%
FCF yield
2.9%
TTM · current market cap
Buyback yield
1.5%
P / FCF
35.0
reciprocal yield 2.9%
P / operating cash flow
30.9
reciprocal yield 3.2%
Earnings yield
3.3%

Historical valuation

8 metrics
P / E historical average (3Y)
28.4×
reciprocal yield 3.5%
P / E historical average (5Y)
26.9×
reciprocal yield 3.7%
EV / revenue historical average (3Y)
9.6×
reciprocal yield 10.4%
EV / revenue historical average (5Y)
8.8×
reciprocal yield 11.4%
EV / EBIT historical average (3Y)
23.5×
reciprocal yield 4.3%
EV / EBIT historical average (5Y)
20.5×
reciprocal yield 4.9%
EV / EBITDA historical average (3Y)
22.0×
reciprocal yield 4.5%
EV / EBITDA historical average (5Y)
19.7×
reciprocal yield 5.1%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-02
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
86.0%
Operating margin
38.0%
Trailing 12 months
Net margin
35.0%
Gross profit (TTM)
$10.82B
Operating profit (TTM)
$4.78B
Net income (TTM)
$4.41B
Trailing 12 months
Diluted EPS (TTM)
$17.17
FCF margin
30.2%
Effective tax rate
16.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$49.12
Gross profit per diluted share (TTM)
$42.24
Operating profit per diluted share (TTM)
$18.64
EBITDA per diluted share (TTM)
$19.51
Net income per diluted share (TTM)
$17.19
Operating cash flow per diluted share (TTM)
$16.75
Free cash flow per diluted share (TTM)
$14.81
Capital expenditures per diluted share (TTM)
$1.94
R&D per diluted share (TTM)
$15.24
Stock compensation per diluted share (TTM)
$2.69
Book value per share
$73.49

Growth

11 metrics
Revenue growth YoY
+12.5%
Year over year
Net income growth YoY
+6.5%
Revenue (TTM)
$12.59B
Trailing 12 months
EPS growth YoY
+8.0%
Shares change YoY
-1.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+10.4%
Revenue CAGR (5Y)
+14.1%
EPS CAGR (3Y)
+6.1%
EPS CAGR (5Y)
+8.3%
FCF CAGR (3Y)
-6.6%
FCF CAGR (5Y)
+1.3%

Quality

14 metrics
Return on equity
21.8%
Return on assets
16.1%
Debt / equity
0.0
Current ratio
3.2
EBITDA (TTM)
$5.00B
Free cash flow (TTM)
$3.80B
Quick ratio
2.7
Interest coverage
—
Net debt / EBITDA
-1.6
Return on invested capital
32.2%
Trailing 12 months
Net cash
$7.85B
Latest balance sheet
Cash & equivalents
$6.14B
Total assets
$27.42B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.29B
Capital expenditures (TTM)
$496.80M
R&D (TTM)
$3.91B
SG&A (TTM)
$2.01B
Stock compensation (TTM)
$689.10M
R&D / revenue
31.0%
Stock compensation / revenue
5.5%

Ownership (13F)

9 metrics
13F filers
1,777
13F filer change QoQ
+67
Institutional ownership
96.4%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
13.3%
Private-fund adviser ownership
12.9%
Active holders' share change QoQ
+1.9%
Holder tenure
18.9
Price vs estimated holder cost
+15.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
18.3%

Short interest

3 metrics
Short interest
1.8%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 875320 CUSIP 92532F100 13F (30d) 508 filings 485 filers Visit website Investor relations